Navigation Links
Illinois Radiologists Self-Edit Reports, Reduce Turnaround Time with SpeechQ for Radiology(TM)
Date:3/19/2008

ase physician satisfaction, and lower operational costs. For more information, please visit http://www.medquist.com.

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that SpeechQ for Radiology does not perform as designed. Actual outcomes and results may differ materially from what is expressed or forecasted in forward- looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE MedQuist, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Delta Dental of Illinois Introduces Smile Smart For Your Health
2. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
3. AmerisourceBergen Technology Group Opens New Facility in Buffalo Grove, Illinois
4. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
5. Health Care Service Corporation Provides Personal Clinical Summaries to Members of its Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas
6. Illinois AARP Presses for Expansion of Childrens Health Insurance Program (SCHIP)
7. Y-ME Illinois Hosts the First-Ever BIG Night Out - Indulgence for a Cause
8. Doctors of Optometry Applaud New Law Requiring Eye Exams for Illinois Children
9. Illinois Planning Board Approves Central DuPage Hospital Bed Pavilion
10. Marianjoy Rehabilitation Hospital to Receive James Brady Award From Brain Injury Association of Illinois
11. Haughton-Pitts Joins AARP Illinois Executive Council
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced ... Hospital, University of London during a session at ... Meeting updated results from the pivotal phase III ... "PIX 301 EXTEND trial") in relapsed or refractory, ... failed 2 or more prior therapies. Updated analyses ...
(Date:12/6/2009)... Pharmacyclics, Inc. (Nasdaq: PCYC ) ... study showing safety and clinical activity in patients ... with its HDAC inhibitor PCI-24781 as a single ... 51st ASH Annual Meeting being held in New ... is an oral pan-HDAC inhibitor which is currently ...
(Date:12/6/2009)... Researchers find signs of feline DNA in virus , , SUNDAY, ... that causes AIDS might be found in a tiger that ... , It appears the virus took on a bit ... of that cat remains in the virus to this day. ... off an evolution of the virus that ultimately led to ...
(Date:12/6/2009)... A new study provides welcome news for patients ... (VTE). , The condition is estimated to impact ... when an abnormal clot forms in a vein and ... In some cases, the clot may detach from its ... the lungs, causing a potentially fatal condition known as ...
(Date:12/5/2009)... 5 There have been significant scientific advances in ... to gain a better understanding of how certain diseases ... provide patients with the best care. Research presented today ... of Hematology explores optimal induction therapies for managing multiple ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... WASHINGTON, Oct. 28 AUL Action is releasing,an open letter ... and Sen. Obama,s promise to sign it., Dr. Charmaine ... don,t even know about this radical bill . . . ... priority in the White House.", FOCA would wipe away ...
... by San Diego,fitness divas, Dr. Steve Laverson ... Carlsbad, CA developed a new abdominoplasty (tummy ... fit appearance than,traditional tummy tuck procedures. The ... to suggest a naturally trim, youthful,feminine torso., ...
... Home health industry,leaders today announced the launch ... (AHHQI) to support education and research, and to,demonstrate ... families and,policymakers. The group is dedicated to improving ... innovative solutions aimed at achieving,optimal clinical outcomes that ...
... Can Directly Interact with Harvard Medical Doctors Via New,Series ... Live Chat with Dr. Julie Silver, Harvard Medical School ... p.m. EDT, BOSTON, Oct. 28 Beginning today, ... Harvard Medical doctor -without,leaving your laptop. Gather (http://www.gather.com ...
... Oct. 28 The average American child,already consumes two ... more than,double the USDA recommended limit of one pound ... Halloween week and often replaces consumption of,healthy food, which ... according to Ask.com Nutritional Expert Elisa Zied, MS, RD, ...
... October, Breast Cancer Awareness,Month, draws to a close, ... that it is truly a year-round effort, and ... care and awareness for its members.,The BCBSGa Breast ... and their physicians, has helped more than 16,000 ...
Other Medicine News:Health News:New Tummy Tuck Technique Increases Sensuality 2Health News:Home Health Leaders Launch Alliance to Sponsor Research and to Educate Public and Policymakers on Sector's Contributions to National Health Reform 2Health News:Home Health Leaders Launch Alliance to Sponsor Research and to Educate Public and Policymakers on Sector's Contributions to National Health Reform 3Health News:Gather and Harvard Health Publications Launch New Programs to Bring Harvard Medical School Doctors' Expertise Online 2Health News:Ask.com and American Dietetic Association Collaborate to Help Parents Avoid Sugar-Induced 'Halloween Hangover' in Kids 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 3
(Date:12/4/2009)... Bayer Diabetes Care today announced the three grand prize winners ... of the Jonas Brothers, selected the winning video entries submitted ... prize is an in-person meeting today with Nick. ... are: Caleb, age 6, from Danbury, CT, who dreams of ...
(Date:12/4/2009)... Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC ... and Trademark Office has allowed its patent application on ... the manufacture of the Company,s DCVax® therapeutic cancer vaccines. ... very high concentration of dendritic cells (which are the ...
(Date:12/4/2009)... Depression, anxiety disorder, bipolar disorder, Attention Deficit ... are among the comorbidities reported to occur more ... diagnosed with epilepsy versus those without an epilepsy ... households across the U.S. ,, Findings from " ...
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3International conference on endothelin 9866 1International conference on endothelin 9866 2International conference on endothelin 9866 3Sex talk revelations of the lonely Y chromosome 9861 1Sex talk revelations of the lonely Y chromosome 9861 2Martek Announces Settlement of Patent Dispute with Capsugel France 13980 1Martek Announces Settlement of Patent Dispute with Capsugel France 13980 2
... PGL; Nasdaq: PGLA) today announced additional,data from the Phase ... This data was presented at the 58th Annual Meeting ... in Boston, USA(1). As the Phase 2 trial,s ... analysis described in this presentation was performed to,evaluate the ...
... as many injections as standard therapy, and, demonstrated at least comparable ... impairment of quality of life on treatment -,- ... presented at the Annual Meeting of the American Association for ... the Study of Liver Diseases (AASLD) -, ROCKVILLE, Md., Nov. 5 ...
Other Medicine Technology:Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C 2Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C 3Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C 4Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C 5Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C 6Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C 7Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C 8
... made of Kydex and soft ... back sections are adjustable in ... facilitate air circulation and tube ... washable. Model C-18 is available ...
Foam Cervical Collar is medium-firm density. Breathable. Deeply anatomically contoured. Natural color, 100% cotton stockinette-covered for comfort. 2" hook and loop closures are another mark of quali...
Ezy Wrap® Economy Contour Cervical Collar Medium-density urethane foam. Synthetic white stockinette cover. Reverses for flexion or extension. (Contact closure. Hand wash. Air dry. 10/pack.)...
Exo-Deluxe Overhead Traction for hospital or home care. Twice the clearance of other units between the patient and supporting wall. 2" nylon pulleys with polypropylene cord, head halter, spreader bar...
Medicine Products: